MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis

• Robert N. Booher,

  Affiliation Discovery Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Harold Hatch,

  Affiliation Discovery Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Brian M. Dolinski,

  Affiliation Discovery Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Thi Nguyen,

  Affiliation Discovery Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Lauren Harmonay,

  Affiliation Discovery Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Ali-Samer Al-Assaad,

  Affiliation Discovery Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Mark Ayers,

  Affiliation BioInformatics, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Michael Nebozhyn,

  Affiliation BioInformatics, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Andrey Loboda,

  Affiliation BioInformatics, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Heather A. Hirsch,

  Affiliation BioInformatics, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Theresa Zhang,

  Affiliation BioInformatics, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Bin Shi,

  Affiliation In vivo Pharmacology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Carrie E. Merkel,

  Affiliation In vivo Pharmacology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Minilik H. Angagaw,

  Affiliation In vivo Pharmacology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Yaolin Wang,

  Affiliation In vivo Pharmacology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Brian J. Long,

  Affiliation In vivo Pharmacology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Xianlu Q. Lennon,

  Affiliation Biomarkers, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Nathan Miselis,

  Affiliation Biomarkers, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Vincenzo Pucci,

  Affiliation Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• James W. Monahan,

  Affiliation Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Junghoon Lee,

  Affiliation Quantitative Pharmacology and Pharmacometrics, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Anna Georgieva Kondic,

  Affiliation Quantitative Pharmacology and Pharmacometrics, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Eun Kyung Im,

  Affiliation Clinical Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• David Mauro,

  Affiliation Clinical Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Rebecca Blanchard,

  Affiliation Clinical Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Gary Gilliland,

  Affiliation Clinical Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Stephen E. Fawell,

  Current address: AstraZeneca, Waltham, Massachusetts, United States of America

  Affiliation Discovery Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Leigh Zawel,

  Affiliation Discovery Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• Alwin G. Schuller,

  Current address: AstraZeneca, Waltham, Massachusetts, United States of America

  Affiliation In vivo Pharmacology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
•  [ ... ],
• Peter Strack

  * E-mail: cpstrack@verizon.net

  Affiliation Discovery Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America

  ⨯
• [ view all ]
• [ view less ]